MedImmune Appoints Development Leadership Team
This article was originally published in The Pink Sheet Daily
Former Cambridge Antibody Technology exec to oversee product development.
You may also be interested in...
MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.
Deal for Cambridge Antibody Technology, valued at $1.07 bil., will shift focus of AstraZeneca’s pipeline.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.